Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boston Scientific Corporation
RESET is a multicenter trial that will assess the effect of pacing in heart failure patients with a normal ejection fraction (or diastolic heart failure). The purpose of the RESET study is to evaluate the effect of pacing on exercise capacity and quality of life in this heart failure population.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who are in sinus rhythm
Patients who are on stable medical therapy
Patients who exhibit signs and symptoms of heart failure, New York Heart Association (NYHA) Class II or III
Patients who have experienced a hospitalization for decompensated heart failure; treatment for pulmonary congestion or volume overload; chronic treatment with a loop diuretic; or a brain natriuretic peptide (BNP) \> 125 ng/l.
Left ventricular ejection fraction (LVEF) ≥ 50%
You may not be if
Patients with persistent atrial fibrillation or atrial flutter
Patients who are in complete heart block
Patients who have experienced a recent myocardial infarction (MI) or have unstable angina or require cardiac surgery or other procedures
Patients who have severe heart valve disease or valve replacement
Patients with a contraindication for a pacemaker system
Patients who have a neuromuscular, orthopedic or other non-cardiac condition that prevents patient from exercise testing
Patients who have infiltrative or hypertrophic cardiomyopathy
Patients who have known severe pulmonary disease
Patients with uncontrolled diabetes or blood pressure (systolic blood pressure (SBP) \> 160 mmHg or diastolic blood pressure (DBP) \> 95 mmHg)
